DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,074 filers reported holding DANAHER CORPORATION in Q4 2022. The put-call ratio across all filers is 1.10 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $66,734 | -99.9% | 251,429 | +0.7% | 1.72% | -5.8% |
Q3 2022 | $64,463,000 | +1.5% | 249,575 | -0.4% | 1.82% | +7.9% |
Q2 2022 | $63,526,000 | -13.3% | 250,576 | +0.4% | 1.69% | +1.1% |
Q1 2022 | $73,237,000 | -11.3% | 249,673 | -0.6% | 1.67% | -6.4% |
Q4 2021 | $82,603,000 | +7.9% | 251,065 | -0.2% | 1.78% | -0.6% |
Q3 2021 | $76,559,000 | +12.5% | 251,476 | -0.8% | 1.79% | +10.9% |
Q2 2021 | $68,029,000 | +18.7% | 253,498 | -0.4% | 1.62% | +10.1% |
Q1 2021 | $57,290,000 | +1.5% | 254,533 | +0.1% | 1.47% | -5.1% |
Q4 2020 | $56,463,000 | +2.2% | 254,177 | -0.9% | 1.55% | -8.9% |
Q3 2020 | $55,245,000 | +19.2% | 256,559 | -2.1% | 1.70% | +9.3% |
Q2 2020 | $46,339,000 | +27.0% | 262,054 | -0.6% | 1.55% | +8.8% |
Q1 2020 | $36,487,000 | -10.0% | 263,614 | -0.2% | 1.43% | +10.8% |
Q4 2019 | $40,537,000 | +6.6% | 264,120 | +0.3% | 1.29% | +0.5% |
Q3 2019 | $38,026,000 | +0.1% | 263,284 | -0.9% | 1.28% | -1.5% |
Q2 2019 | $37,988,000 | +7.3% | 265,803 | -0.9% | 1.30% | +3.7% |
Q1 2019 | $35,404,000 | +27.9% | 268,175 | -0.1% | 1.26% | +14.7% |
Q4 2018 | $27,671,000 | -5.4% | 268,339 | -0.3% | 1.09% | +9.0% |
Q3 2018 | $29,250,000 | +12.0% | 269,191 | +1.7% | 1.00% | +3.7% |
Q2 2018 | $26,122,000 | +0.8% | 264,711 | +0.1% | 0.97% | -0.2% |
Q1 2018 | $25,905,000 | +21.0% | 264,576 | +14.7% | 0.97% | +26.8% |
Q4 2017 | $21,407,000 | +22.9% | 230,625 | +13.6% | 0.76% | +18.4% |
Q3 2017 | $17,419,000 | +3.9% | 203,071 | +2.2% | 0.65% | +1.4% |
Q2 2017 | $16,767,000 | +0.8% | 198,688 | +2.2% | 0.64% | -2.3% |
Q1 2017 | $16,635,000 | +9.5% | 194,493 | -0.4% | 0.65% | +5.0% |
Q4 2016 | $15,197,000 | -2.0% | 195,232 | -1.3% | 0.62% | -3.4% |
Q3 2016 | $15,507,000 | -23.3% | 197,816 | -1.2% | 0.64% | -24.0% |
Q2 2016 | $20,225,000 | +6.2% | 200,251 | -0.3% | 0.85% | +4.3% |
Q1 2016 | $19,052,000 | +2.4% | 200,842 | +0.3% | 0.81% | +0.5% |
Q4 2015 | $18,599,000 | +9.5% | 200,249 | +0.5% | 0.81% | +4.5% |
Q3 2015 | $16,980,000 | -0.6% | 199,269 | -0.2% | 0.77% | +7.1% |
Q2 2015 | $17,083,000 | +17.9% | 199,586 | +16.9% | 0.72% | +15.5% |
Q1 2015 | $14,491,000 | +0.1% | 170,688 | +1.1% | 0.62% | +0.5% |
Q4 2014 | $14,474,000 | +14.1% | 168,867 | +1.1% | 0.62% | +10.9% |
Q3 2014 | $12,688,000 | -2.1% | 166,994 | +1.5% | 0.56% | -2.1% |
Q2 2014 | $12,954,000 | +3.7% | 164,534 | +0.8% | 0.57% | -1.7% |
Q1 2014 | $12,490,000 | -0.7% | 163,284 | +0.2% | 0.58% | -1.4% |
Q4 2013 | $12,584,000 | +14.3% | 163,004 | +2.6% | 0.59% | +4.1% |
Q3 2013 | $11,012,000 | +9.7% | 158,851 | +0.2% | 0.57% | +4.2% |
Q2 2013 | $10,036,000 | – | 158,551 | – | 0.54% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |